Welcome
Support Centre
25 October 2014 
ISRCTN Register - International Standard Randomized Controlled Trial Number
Trial registration
Unique identification scheme
International databases
home  |   my details  |   ISRCTN Register  |   mRCT  |   links  |   information  |   news
Find trials
ISRCTN Register
tips on searching

Registration
New application
Updating record

Information
introduction
governing board
ISRCTN FAQs
data set
letter of agreement
request information
guidance notes
statistics

[ Print-friendly version ]
Assessing the impact of escalating fish oil consumption on n-3 polyunsaturated fatty acid (PUFA) content of transport, storage and functional pools
ISRCTN ISRCTN48398526
DOI 10.1186/ISRCTN48398526
ClinicalTrials.gov identifier
EudraCT number
Public title Assessing the impact of escalating fish oil consumption on n-3 polyunsaturated fatty acid (PUFA) content of transport, storage and functional pools
Scientific title Assessing the impact of escalating fish oil consumption on n-3 polyunsaturated fatty acid (PUFA) content of transport, storage and functional pools: a randomised controlled trial
Acronym FISH
Serial number at source N05065/N05066
Study hypothesis This two-centre study will determine the effect of long-chain (LC) n-3 PUFA supplementation on the fatty acid (FA) content of plasma phospholipids, triacylglycerols, cholesteryl esters and non-esterified fatty acids, platelets, erythrocytes, leukocytes and adipose tissue. Relationships between FA status of different pools and differences according to age and gender will be determined. The intervention is capsule based, to maximise compliance, but will provide LC n-3 PUFA as 'portions' in doses designed to mimic oily fish consumption in free-living.

Please note that, as of 16/01/2009, the anticipated end date of this trial has been amended from 31/12/2008 to 28/02/2009.
Lay summary http://www.mrc-hnr.cam.ac.uk/research/research-sections/diet-population-health/dph-projects/fish-study
Ethics approval Suffolk Research Ethics Committee (REC), approved on 06/02/2006 (ref: 05/Q0102/181)
Study design Randomised controlled trial
Countries of recruitment United Kingdom
Disease/condition/study domain Impact of fish-oil consumption on the fatty acid content of plasma
Participants - inclusion criteria Men and women, aged 20-80 years with a body mass index (BMI) in the range 18-35 kg/m^2 will be recruited to the study.
Participants - exclusion criteria 1. Known diagnosis of diabetes, cancer, cardiovascular disease or other chronic clinical conditions
2. Untreated hypertension
3. Concomitant prescription of anticoagulants, non-steroidal anti-inflammatory drugs (NSAIDS), aspirin, steroids or immunosuppressants
4. Following a special diet, including vegetarians
5. Allergies or intolerance to fish
6. Consumption of oily fish more than once a month
7. Smokers
8. History of substance abuse or alcoholism
9. Pregnant, <1 year post partum or currently planning pregnancy
10. Recent weight change (>2 kg in past 1 month)
11. Planning to change dietary habits, increase physical activity, change body weight, move away from the study centre locality or take a lengthy vacation during the time of the study
Anticipated start date 01/05/2006
Anticipated end date 28/02/2009
Status of trial Completed
Patient information material
Target number of participants 210
Interventions The five treatment groups are:
1. Control group (n = 42)
2. Capsules equivalent to 1 portion of oily fish per week (containing approximately 1.8 g eicosapentaenoic acid [EPA] and 1.5 g docosahexaenoic acid [DHA] per week) (n = 42)
3. Capsules equivalent to 2 portions of oily fish per week (containing approximately 3.6 g EPA and 3.0 g DHA per week) (n = 42)
4. Capsules equivalent to 2 portions of oily fish per week, taken continuously rather than in a 'portion' (containing approximately 3.6 g EPA and 3.0 g DHA per week) (n = 42)
5. Capsules equivalent to 4 portions of oily fish per week (containing approximately 7.2 g EPA and 6.0 g DHA per week) (n = 42)
Primary outcome measure(s) The primary outcome is plasma docosahexaenoic acid (DHA) status, expressed as a percentage of total plasma fatty acids.

The three primary comparisons (on which sample size has been calculated) are:
1. Differences in plasma DHA status between treatment groups (2 portions versus control group) at 12 months
2. Differences in plasma DHA status between treatment groups (4 portions versus 2 portions group) at 12 months
3. Difference in plasma DHA status between age groups (old versus young) at 12 months
Secondary outcome measure(s) Secondary comparisons will include gender effects, additional age comparisons and within-group time relationships. Additionally, interactions between portions, age, time and gender will be explored.

Secondary outcomes will include DHA status of other fatty acid pools (also expressed as a percentage of the total fatty acid profile).
Sources of funding Food Standards Agency (UK) (ref: N05065/N05066)
Trial website
Publications 2012 results in: http://www.ncbi.nlm.nih.gov/pubmed/22932281
2014 results in: http://www.ncbi.nlm.nih.gov/pubmed/24647395
Contact name Dr  Celia  Walker
  Address MRC Human Nutrition Research
Fulbourn Road
  City/town Cambridge
  Zip/Postcode CB1 9NL
  Country United Kingdom
  Tel +44 (0)1223 426356
  Fax +44 (0)1223 437515
  Email celia.walker@mrc-hnr.cam.ac.uk
Sponsor MRC Human Nutrition Research (UK)
  Address Elsie Widdowson Laboratory
Fulbourn Road
  City/town Cambridge
  Zip/Postcode CB1 9NL
  Country United Kingdom
Date applied 21/03/2006
Last edited 11/06/2014
Date ISRCTN assigned 28/04/2006
Submit your trial protocol
Submit to Trials journal
Follow us on Twitter
© 2014 ISRCTN unless otherwise stated.